{"transactions":[{"id":905309,"issuer":{"id":4757,"kind":"organization","name":"Jade Biosciences, Inc."},"owners":[{"id":66503,"kind":"person","name":"King Andrew James","position":1,"cik":"0001823187","reported_name":"King Andrew James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-14T01:00:19.000Z","date":"2026-02-12","kind":"grant","planned":false,"acquired":true,"shares":247500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option represents a right to purchase shares of the Issuer's common stock, one quarter of which will vest on February 15, 2027, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date."}],"balance_after":247500,"derivative":{"exercise_price":14.81,"expiration_date":"2036-02-11","underlying":"Common Stock","underlying_shares":247500},"source":{"system":"sec-edgar","filing":"0001193125-26-052053","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1798749/000119312526052053/ownership.xml","form_type":"4"}},{"id":905308,"issuer":{"id":4757,"kind":"organization","name":"Jade Biosciences, Inc."},"owners":[{"id":66503,"kind":"person","name":"King Andrew James","position":1,"cik":"0001823187","reported_name":"King Andrew James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-02-14T01:00:19.000Z","date":"2026-02-12","kind":"grant","planned":false,"acquired":true,"shares":41250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\"). 1/4 of the total number of RSUs granted shall vest on each of the first four anniversaries of February 15, 2026, the vesting commencement date, subject to the Reporting Person's continued service through each vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer."}],"balance_after":386113,"source":{"system":"sec-edgar","filing":"0001193125-26-052053","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1798749/000119312526052053/ownership.xml","form_type":"4"}},{"id":1809823,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":66503,"kind":"person","name":"King Andrew James","position":1,"cik":"0001823187","reported_name":"King Andrew James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2023-08-11T16:09:52.000Z","date":"2023-08-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":8400,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F9","text":"When granted, each restricted stock unit (\"RSU\") represented a contingent right to receive one share of the Issuer's Common Stock upon settlement."},{"field":"price","element":"transactionPricePerShare","label":"F15","text":"When granted, the RSU award provided for the vesting of restricted stock units for shares of the Issuer's Common Stock contingent upon the achievement of certain performance-based vesting conditions.   Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F15","text":"When granted, the RSU award provided for the vesting of restricted stock units for shares of the Issuer's Common Stock contingent upon the achievement of certain performance-based vesting conditions.   Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F15","text":"When granted, the RSU award provided for the vesting of restricted stock units for shares of the Issuer's Common Stock contingent upon the achievement of certain performance-based vesting conditions.   Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":8400},"source":{"system":"sec-edgar","filing":"0001209191-23-045424","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000120919123045424/doc4.xml","form_type":"4"}},{"id":1809822,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":66503,"kind":"person","name":"King Andrew James","position":1,"cik":"0001823187","reported_name":"King Andrew James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2023-08-11T16:09:52.000Z","date":"2023-08-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":26000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F9","text":"When granted, each restricted stock unit (\"RSU\") represented a contingent right to receive one share of the Issuer's Common Stock upon settlement."},{"field":"price","element":"transactionPricePerShare","label":"F14","text":"When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on January 31, 2024.  Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F14","text":"When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on January 31, 2024.  Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F14","text":"When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on January 31, 2024.  Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":26000},"source":{"system":"sec-edgar","filing":"0001209191-23-045424","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000120919123045424/doc4.xml","form_type":"4"}},{"id":1809821,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":66503,"kind":"person","name":"King Andrew James","position":1,"cik":"0001823187","reported_name":"King Andrew James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2023-08-11T16:09:52.000Z","date":"2023-08-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":6667,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F9","text":"When granted, each restricted stock unit (\"RSU\") represented a contingent right to receive one share of the Issuer's Common Stock upon settlement."},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on July 29, 2022. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F13","text":"When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on July 29, 2022. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F13","text":"When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on July 29, 2022. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":6667},"source":{"system":"sec-edgar","filing":"0001209191-23-045424","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000120919123045424/doc4.xml","form_type":"4"}},{"id":1809820,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":66503,"kind":"person","name":"King Andrew James","position":1,"cik":"0001823187","reported_name":"King Andrew James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2023-08-11T16:09:52.000Z","date":"2023-08-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":16667,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F9","text":"When granted, each restricted stock unit (\"RSU\") represented a contingent right to receive one share of the Issuer's Common Stock upon settlement."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on January 31, 2023.  Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on January 31, 2023.  Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F12","text":"When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on January 31, 2023.  Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":16667},"source":{"system":"sec-edgar","filing":"0001209191-23-045424","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000120919123045424/doc4.xml","form_type":"4"}},{"id":1809819,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":66503,"kind":"person","name":"King Andrew James","position":1,"cik":"0001823187","reported_name":"King Andrew James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2023-08-11T16:09:52.000Z","date":"2023-08-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":6802,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F9","text":"When granted, each restricted stock unit (\"RSU\") represented a contingent right to receive one share of the Issuer's Common Stock upon settlement."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on February 10, 2022.  Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on February 10, 2022.  Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F11","text":"When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on February 10, 2022.  Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":6802},"source":{"system":"sec-edgar","filing":"0001209191-23-045424","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000120919123045424/doc4.xml","form_type":"4"}},{"id":1809818,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":66503,"kind":"person","name":"King Andrew James","position":1,"cik":"0001823187","reported_name":"King Andrew James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2023-08-11T16:09:52.000Z","date":"2023-08-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10152,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F9","text":"When granted, each restricted stock unit (\"RSU\") represented a contingent right to receive one share of the Issuer's Common Stock upon settlement."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on October 6, 2021. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on October 6, 2021. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F10","text":"When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on October 6, 2021. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":10152},"source":{"system":"sec-edgar","filing":"0001209191-23-045424","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000120919123045424/doc4.xml","form_type":"4"}},{"id":1809817,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":66503,"kind":"person","name":"King Andrew James","position":1,"cik":"0001823187","reported_name":"King Andrew James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-11T16:09:52.000Z","date":"2023-08-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":104000,"price":14.73,"value":1531920.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"This stock option award, which provided for 25% of the award to vest on January 31, 2024 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":25.27,"expiration_date":"2033-01-30","underlying":"Common Stock","underlying_shares":104000},"source":{"system":"sec-edgar","filing":"0001209191-23-045424","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000120919123045424/doc4.xml","form_type":"4"}},{"id":1809816,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":66503,"kind":"person","name":"King Andrew James","position":1,"cik":"0001823187","reported_name":"King Andrew James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-11T16:09:52.000Z","date":"2023-08-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":100000,"price":27.1,"value":2710000.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"This stock option award, which provided for 25% of the award to vest on January 31, 2023 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":12.9,"expiration_date":"2032-01-30","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001209191-23-045424","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000120919123045424/doc4.xml","form_type":"4"}},{"id":1809815,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":66503,"kind":"person","name":"King Andrew James","position":1,"cik":"0001823187","reported_name":"King Andrew James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-11T16:09:52.000Z","date":"2023-08-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":21500,"price":22.41,"value":481815.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This stock option award, which provided for 25% of the award to vest on June 7, 2022 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":17.59,"expiration_date":"2031-06-06","underlying":"Common Stock","underlying_shares":21500},"source":{"system":"sec-edgar","filing":"0001209191-23-045424","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000120919123045424/doc4.xml","form_type":"4"}},{"id":1809814,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":66503,"kind":"person","name":"King Andrew James","position":1,"cik":"0001823187","reported_name":"King Andrew James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-11T16:09:52.000Z","date":"2023-08-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":60000,"price":24.86,"value":1491600.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This stock option award, which provided for 25% of the award to vest on February 10, 2022 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":15.14,"expiration_date":"2031-02-09","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001209191-23-045424","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000120919123045424/doc4.xml","form_type":"4"}},{"id":1809813,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":66503,"kind":"person","name":"King Andrew James","position":1,"cik":"0001823187","reported_name":"King Andrew James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-11T16:09:52.000Z","date":"2023-08-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":89545,"price":25.23,"value":2259220.35,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This stock option award, which provided for 25% of the award to vest on October 6, 2021 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":14.77,"expiration_date":"2030-10-05","underlying":"Common Stock","underlying_shares":89545},"source":{"system":"sec-edgar","filing":"0001209191-23-045424","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000120919123045424/doc4.xml","form_type":"4"}},{"id":1809812,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":66503,"kind":"person","name":"King Andrew James","position":1,"cik":"0001823187","reported_name":"King Andrew James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-11T16:09:52.000Z","date":"2023-08-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":73047,"price":39.58,"value":2891200.26,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This stock option award, which provided for 25% of the award to vest on March 6, 2021 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":0.42,"expiration_date":"2030-03-18","underlying":"Common Stock","underlying_shares":73047},"source":{"system":"sec-edgar","filing":"0001209191-23-045424","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000120919123045424/doc4.xml","form_type":"4"}},{"id":1809811,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":66503,"kind":"person","name":"King Andrew James","position":1,"cik":"0001823187","reported_name":"King Andrew James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-11T16:09:52.000Z","date":"2023-08-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":43047,"price":39.65,"value":1706813.55,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award, which provided for 25% of the award to vest on May 6, 2020 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":0.35,"expiration_date":"2029-06-05","underlying":"Common Stock","underlying_shares":43047},"source":{"system":"sec-edgar","filing":"0001209191-23-045424","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000120919123045424/doc4.xml","form_type":"4"}},{"id":1809810,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":66503,"kind":"person","name":"King Andrew James","position":1,"cik":"0001823187","reported_name":"King Andrew James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-08-11T16:09:52.000Z","date":"2023-08-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":19157,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities were disposed of pursuant to the Merger Agreement (defined in the Remarks below).  Upon effectiveness of the Merger (defined in the Remarks below), in exchange for each share of the Issuer's Common Stock, the reporting person received:  (i) $40.00 in cash, without interest and less applicable withholding taxes; and (ii) one contractual contingent value right (each, a \"CVR\"), entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement (the \"Contingent Value Rights Agreement\") entered into concurrent with completion of the Merger."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-23-045424","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000120919123045424/doc4.xml","form_type":"4"}},{"id":1819093,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":66503,"kind":"person","name":"King Andrew James","position":1,"cik":"0001823187","reported_name":"King Andrew James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2023-08-01T19:27:27.000Z","date":"2023-07-29","kind":"exercise","planned":false,"acquired":false,"shares":3333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each RSU represents a contingent right to receive one share of Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs vest as to one-third (1/3) of the total award on the first, second, and third anniversaries of the grant date, subject to the reporting person's continued service to the Issuer on each vesting date."}],"balance_after":6667,"derivative":{"expiration_date":"2025-07-29","underlying":"Common Stock","underlying_shares":3333},"source":{"system":"sec-edgar","filing":"0001209191-23-044071","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000120919123044071/doc4.xml","form_type":"4"}},{"id":1819092,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":66503,"kind":"person","name":"King Andrew James","position":1,"cik":"0001823187","reported_name":"King Andrew James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-08-01T19:27:27.000Z","date":"2023-08-01","kind":"sale","planned":false,"acquired":false,"shares":1168,"price":39.029,"value":45585.872,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a \"sell to cover\" transaction and do not represent discretionary trades by the Reporting Person."}],"balance_after":19157,"source":{"system":"sec-edgar","filing":"0001209191-23-044071","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000120919123044071/doc4.xml","form_type":"4"}},{"id":1819091,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":66503,"kind":"person","name":"King Andrew James","position":1,"cik":"0001823187","reported_name":"King Andrew James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-08-01T19:27:27.000Z","date":"2023-07-29","kind":"exercise","planned":false,"acquired":true,"shares":3333,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units (\"RSUs\") convert into common stock on a one-for-one basis."}],"balance_after":20325,"source":{"system":"sec-edgar","filing":"0001209191-23-044071","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000120919123044071/doc4.xml","form_type":"4"}},{"id":1924880,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":66503,"kind":"person","name":"King Andrew James","position":1,"cik":"0001823187","reported_name":"King Andrew James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-04-05T16:43:08.000Z","date":"2023-04-03","kind":"exercise","planned":true,"acquired":false,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vested as to 25% of the total shares on May 6, 2020, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date."}],"balance_after":43047,"derivative":{"exercise_price":0.35,"expiration_date":"2029-06-05","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001209191-23-023351","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000120919123023351/doc4.xml","form_type":"4"}},{"id":1924879,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":66503,"kind":"person","name":"King Andrew James","position":1,"cik":"0001823187","reported_name":"King Andrew James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-04-05T16:43:08.000Z","date":"2023-04-03","kind":"sale","planned":true,"acquired":false,"shares":5000,"price":23.3435,"value":116717.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 2, 2022"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.98 to $23.67, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein."}],"balance_after":16992,"source":{"system":"sec-edgar","filing":"0001209191-23-023351","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000120919123023351/doc4.xml","form_type":"4"}},{"id":1924878,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":66503,"kind":"person","name":"King Andrew James","position":1,"cik":"0001823187","reported_name":"King Andrew James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-04-05T16:43:08.000Z","date":"2023-04-03","kind":"exercise","planned":true,"acquired":true,"shares":2500,"price":0.35,"value":875.0,"ownership":{"direct":true},"balance_after":21992,"source":{"system":"sec-edgar","filing":"0001209191-23-023351","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000120919123023351/doc4.xml","form_type":"4"}},{"id":2013448,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":66503,"kind":"person","name":"King Andrew James","position":1,"cik":"0001823187","reported_name":"King Andrew James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2023-02-15T16:39:14.000Z","date":"2023-02-10","kind":"exercise","acquired":false,"shares":6803,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each RSU represents a contingent right to receive one share of Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs vests as to one-third (1/3) of the total restricted stock units in equal annual installments beginning on February 10, 2022, until fully vested, subject to the reporting person's provision of service to the Issuer on each vesting date."}],"balance_after":6802,"derivative":{"expiration_date":"2024-02-10","underlying":"Common Stock","underlying_shares":6803},"source":{"system":"sec-edgar","filing":"0001209191-23-009766","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000120919123009766/doc4.xml","form_type":"4"}},{"id":2013447,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":66503,"kind":"person","name":"King Andrew James","position":1,"cik":"0001823187","reported_name":"King Andrew James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-02-15T16:39:14.000Z","date":"2023-02-10","kind":"sale","acquired":false,"shares":2392,"price":23.7485,"value":56806.412,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a \"sell to cover\" transaction and do not represent discretionary trades by the Reporting Person."}],"balance_after":19492,"source":{"system":"sec-edgar","filing":"0001209191-23-009766","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000120919123009766/doc4.xml","form_type":"4"}},{"id":2013446,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":66503,"kind":"person","name":"King Andrew James","position":1,"cik":"0001823187","reported_name":"King Andrew James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-02-15T16:39:14.000Z","date":"2023-02-10","kind":"exercise","acquired":true,"shares":6803,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units (\"RSUs\") convert into common stock on a one-for-one basis."}],"balance_after":21884,"source":{"system":"sec-edgar","filing":"0001209191-23-009766","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000120919123009766/doc4.xml","form_type":"4"}},{"id":2035817,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":66503,"kind":"person","name":"King Andrew James","position":1,"cik":"0001823187","reported_name":"King Andrew James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Unit","published_at":"2023-02-02T18:13:45.000Z","date":"2023-01-31","kind":"grant","acquired":true,"shares":26000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The RSUs vests as to one-third (1/3) of the total restricted stock units in equal annual installments beginning on January 31, 2024, until fully vested, subject to the reporting person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The RSUs vests as to one-third (1/3) of the total restricted stock units in equal annual installments beginning on January 31, 2024, until fully vested, subject to the reporting person's provision of service to the Issuer on each vesting date."}],"balance_after":26000,"derivative":{"underlying":"Common Stock","underlying_shares":26000},"source":{"system":"sec-edgar","filing":"0001209191-23-006371","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000120919123006371/doc4.xml","form_type":"4"}},{"id":2035816,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":66503,"kind":"person","name":"King Andrew James","position":1,"cik":"0001823187","reported_name":"King Andrew James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-02T18:13:45.000Z","date":"2023-01-31","kind":"grant","acquired":true,"shares":104000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The stock option vests as to 25% of the total shares on January 31, 2024, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":104000,"derivative":{"exercise_price":25.27,"expiration_date":"2033-01-30","underlying":"Common Stock","underlying_shares":104000},"source":{"system":"sec-edgar","filing":"0001209191-23-006371","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000120919123006371/doc4.xml","form_type":"4"}},{"id":2035815,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":66503,"kind":"person","name":"King Andrew James","position":1,"cik":"0001823187","reported_name":"King Andrew James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Unirt","published_at":"2023-02-02T18:13:45.000Z","date":"2023-01-31","kind":"exercise","acquired":false,"shares":8333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs vests as to one-third (1/3) of the total restricted stock units in equal annual installments beginning on January 31, 2023, until fully vested, subject to the reporting person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The RSUs vests as to one-third (1/3) of the total restricted stock units in equal annual installments beginning on January 31, 2023, until fully vested, subject to the reporting person's provision of service to the Issuer on each vesting date."}],"balance_after":16667,"derivative":{"underlying":"Common Stock","underlying_shares":8333},"source":{"system":"sec-edgar","filing":"0001209191-23-006371","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000120919123006371/doc4.xml","form_type":"4"}},{"id":2035814,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":66503,"kind":"person","name":"King Andrew James","position":1,"cik":"0001823187","reported_name":"King Andrew James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-02-02T18:13:45.000Z","date":"2023-01-31","kind":"sale","acquired":false,"shares":3244,"price":24.6822,"value":80069.0568,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a \"sell to cover\" transaction and do not represent discretionary trades by the Reporting Person."}],"balance_after":15081,"source":{"system":"sec-edgar","filing":"0001209191-23-006371","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000120919123006371/doc4.xml","form_type":"4"}},{"id":2035813,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":66503,"kind":"person","name":"King Andrew James","position":1,"cik":"0001823187","reported_name":"King Andrew James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-02-02T18:13:45.000Z","date":"2023-01-31","kind":"exercise","acquired":true,"shares":8333,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units (\"RSUs\") convert into common stock on a one-for-one basis."}],"balance_after":18325,"source":{"system":"sec-edgar","filing":"0001209191-23-006371","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000120919123006371/doc4.xml","form_type":"4"}},{"id":2067044,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":66503,"kind":"person","name":"King Andrew James","position":1,"cik":"0001823187","reported_name":"King Andrew James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-01-04T19:44:44.000Z","date":"2023-01-03","kind":"exercise","acquired":false,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vested as to 25% of the total shares on May 6, 2020, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date."}],"balance_after":45547,"derivative":{"exercise_price":0.35,"expiration_date":"2029-06-05","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001209191-23-001434","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000120919123001434/doc4.xml","form_type":"4"}},{"id":2067043,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":66503,"kind":"person","name":"King Andrew James","position":1,"cik":"0001823187","reported_name":"King Andrew James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-01-04T19:44:44.000Z","date":"2023-01-03","kind":"sale","acquired":false,"shares":10000,"price":25.8183,"value":258183.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.585 to $26.20, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein."}],"balance_after":9992,"source":{"system":"sec-edgar","filing":"0001209191-23-001434","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000120919123001434/doc4.xml","form_type":"4"}},{"id":2067042,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":66503,"kind":"person","name":"King Andrew James","position":1,"cik":"0001823187","reported_name":"King Andrew James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-01-04T19:44:44.000Z","date":"2023-01-03","kind":"exercise","acquired":true,"shares":7500,"price":0.35,"value":2625.0,"ownership":{"direct":true},"balance_after":19992,"source":{"system":"sec-edgar","filing":"0001209191-23-001434","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000120919123001434/doc4.xml","form_type":"4"}},{"id":2139110,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":66503,"kind":"person","name":"King Andrew James","position":1,"cik":"0001823187","reported_name":"King Andrew James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units (RSU)","published_at":"2022-10-11T16:32:28.000Z","date":"2022-10-06","kind":"exercise","acquired":false,"shares":10152,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs vests as to one-third (1/3) of the total restricted stock units in equal annual installments beginning on October 6, 2021, until fully vested subject to the reporting person's provision of service to the Issuer on each vesting date."}],"balance_after":10152,"derivative":{"expiration_date":"2030-10-05","underlying":"Common Stock","underlying_shares":10152},"source":{"system":"sec-edgar","filing":"0001209191-22-053301","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000120919122053301/doc4.xml","form_type":"4"}},{"id":2139109,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":66503,"kind":"person","name":"King Andrew James","position":1,"cik":"0001823187","reported_name":"King Andrew James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2022-10-11T16:32:28.000Z","date":"2022-10-06","kind":"sale","acquired":false,"shares":3557,"price":19.692,"value":70044.444,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a \"sell to cover\" transaction and do not represent discretionary trades by the Reporting Person."}],"balance_after":12492,"source":{"system":"sec-edgar","filing":"0001209191-22-053301","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000120919122053301/doc4.xml","form_type":"4"}},{"id":2139108,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":66503,"kind":"person","name":"King Andrew James","position":1,"cik":"0001823187","reported_name":"King Andrew James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2022-10-11T16:32:28.000Z","date":"2022-10-06","kind":"exercise","acquired":true,"shares":10152,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."}],"balance_after":16049,"source":{"system":"sec-edgar","filing":"0001209191-22-053301","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000120919122053301/doc4.xml","form_type":"4"}},{"id":2193162,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":66503,"kind":"person","name":"King Andrew James","position":1,"cik":"0001823187","reported_name":"King Andrew James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-08-05T17:09:57.000Z","date":"2022-08-04","kind":"exercise","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vested as to 25% of the total shares on May 6, 2020, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date."}],"balance_after":53047,"derivative":{"exercise_price":0.35,"expiration_date":"2029-06-05","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001209191-22-044596","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000120919122044596/doc4.xml","form_type":"4"}},{"id":2193161,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":66503,"kind":"person","name":"King Andrew James","position":1,"cik":"0001823187","reported_name":"King Andrew James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2022-08-05T17:09:57.000Z","date":"2022-08-04","kind":"sale","acquired":false,"shares":5000,"price":20,"value":100000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":5897,"source":{"system":"sec-edgar","filing":"0001209191-22-044596","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000120919122044596/doc4.xml","form_type":"4"}},{"id":2193160,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":66503,"kind":"person","name":"King Andrew James","position":1,"cik":"0001823187","reported_name":"King Andrew James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2022-08-05T17:09:57.000Z","date":"2022-08-04","kind":"exercise","acquired":true,"shares":5000,"price":0.35,"value":1750.0,"ownership":{"direct":true},"balance_after":10897,"source":{"system":"sec-edgar","filing":"0001209191-22-044596","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000120919122044596/doc4.xml","form_type":"4"}},{"id":2197541,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":66503,"kind":"person","name":"King Andrew James","position":1,"cik":"0001823187","reported_name":"King Andrew James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2022-08-02T16:50:10.000Z","date":"2022-07-29","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs vest as to one-third (1/3) of the total award on the first, second, and third anniversaries of the grant date, subject to the reporting person's continued service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"These restricted stock units do not expire; they either vest or are cancelled prior to the vesting date."}],"balance_after":10000,"derivative":{"underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-22-043899","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000120919122043899/doc4.xml","form_type":"4"}},{"id":2207989,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":66503,"kind":"person","name":"King Andrew James","position":1,"cik":"0001823187","reported_name":"King Andrew James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-07-13T16:11:59.000Z","date":"2022-07-11","kind":"exercise","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vested as to 25% of the total shares on May 6, 2020, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date."}],"balance_after":58047,"derivative":{"exercise_price":0.35,"expiration_date":"2029-06-05","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001209191-22-042041","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000120919122042041/doc4.xml","form_type":"4"}},{"id":2207988,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":66503,"kind":"person","name":"King Andrew James","position":1,"cik":"0001823187","reported_name":"King Andrew James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2022-07-13T16:11:59.000Z","date":"2022-07-11","kind":"sale","acquired":false,"shares":5000,"price":18.0936,"value":90468.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.85 to $18.29, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein."}],"balance_after":5897,"source":{"system":"sec-edgar","filing":"0001209191-22-042041","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000120919122042041/doc4.xml","form_type":"4"}},{"id":2207987,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":66503,"kind":"person","name":"King Andrew James","position":1,"cik":"0001823187","reported_name":"King Andrew James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2022-07-13T16:11:59.000Z","date":"2022-07-11","kind":"exercise","acquired":true,"shares":5000,"price":0.35,"value":1750.0,"ownership":{"direct":true},"balance_after":10897,"source":{"system":"sec-edgar","filing":"0001209191-22-042041","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000120919122042041/doc4.xml","form_type":"4"}},{"id":2297661,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":66503,"kind":"person","name":"King Andrew James","position":1,"cik":"0001823187","reported_name":"King Andrew James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-04-13T17:34:29.000Z","date":"2022-04-11","kind":"exercise","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vested as to 25% of the total shares on May 6, 2020, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date."}],"balance_after":63047,"derivative":{"exercise_price":0.35,"expiration_date":"2029-06-05","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001209191-22-024324","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000120919122024324/doc4.xml","form_type":"4"}},{"id":2297660,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":66503,"kind":"person","name":"King Andrew James","position":1,"cik":"0001823187","reported_name":"King Andrew James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2022-04-13T17:34:29.000Z","date":"2022-04-11","kind":"sale","acquired":false,"shares":5000,"price":15.3624,"value":76812.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.15 to $15.68, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein."}],"balance_after":5897,"source":{"system":"sec-edgar","filing":"0001209191-22-024324","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000120919122024324/doc4.xml","form_type":"4"}},{"id":2297659,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":66503,"kind":"person","name":"King Andrew James","position":1,"cik":"0001823187","reported_name":"King Andrew James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2022-04-13T17:34:29.000Z","date":"2022-04-11","kind":"exercise","acquired":true,"shares":5000,"price":0.35,"value":1750.0,"ownership":{"direct":true},"balance_after":10897,"source":{"system":"sec-edgar","filing":"0001209191-22-024324","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000120919122024324/doc4.xml","form_type":"4"}},{"id":2378299,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":66503,"kind":"person","name":"King Andrew James","position":1,"cik":"0001823187","reported_name":"King Andrew James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2022-02-23T17:17:55.000Z","date":"2022-02-18","kind":"sale","acquired":false,"shares":2500,"price":13,"value":32500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":5897,"source":{"system":"sec-edgar","filing":"0001209191-22-012315","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000120919122012315/doc4.xml","form_type":"4"}},{"id":2397738,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":66503,"kind":"person","name":"King Andrew James","position":1,"cik":"0001823187","reported_name":"King Andrew James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units (RSU)","published_at":"2022-02-14T19:56:45.000Z","date":"2022-02-10","kind":"exercise","acquired":false,"shares":6801,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The RSUs vests as to one-third (1/3) of the total restricted stock units in equal annual installments beginning on February 10, 2022, until fully vested, subject to the reporting person's provision of service to the Issuer on each vesting date."}],"balance_after":13605,"derivative":{"expiration_date":"2024-02-10","underlying":"Common Stock","underlying_shares":6801},"source":{"system":"sec-edgar","filing":"0001209191-22-009564","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000120919122009564/doc4.xml","form_type":"4"}},{"id":2397737,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":66503,"kind":"person","name":"King Andrew James","position":1,"cik":"0001823187","reported_name":"King Andrew James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2022-02-14T19:56:45.000Z","date":"2022-02-11","kind":"sale","acquired":false,"shares":2498,"price":12.7411,"value":31827.2678,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a \"sell to cover\" transaction and do not represent discretionary trades by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.64 to $12.74, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein."}],"balance_after":8397,"source":{"system":"sec-edgar","filing":"0001209191-22-009564","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000120919122009564/doc4.xml","form_type":"4"}},{"id":2397736,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":66503,"kind":"person","name":"King Andrew James","position":1,"cik":"0001823187","reported_name":"King Andrew James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2022-02-14T19:56:45.000Z","date":"2022-02-10","kind":"exercise","acquired":true,"shares":6801,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."}],"balance_after":10895,"source":{"system":"sec-edgar","filing":"0001209191-22-009564","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000120919122009564/doc4.xml","form_type":"4"}},{"id":2401452,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":66503,"kind":"person","name":"King Andrew James","position":1,"cik":"0001823187","reported_name":"King Andrew James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-02-11T17:26:33.000Z","date":"2022-02-10","kind":"exercise","acquired":false,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vested as to 25% of the total shares on May 6, 2020, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date."}],"balance_after":68047,"derivative":{"exercise_price":0.35,"expiration_date":"2029-06-05","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001209191-22-008937","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000120919122008937/doc4.xml","form_type":"4"}},{"id":2401451,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":66503,"kind":"person","name":"King Andrew James","position":1,"cik":"0001823187","reported_name":"King Andrew James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2022-02-11T17:26:33.000Z","date":"2022-02-10","kind":"sale","acquired":false,"shares":2500,"price":13.31,"value":33275.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":4094,"source":{"system":"sec-edgar","filing":"0001209191-22-008937","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000120919122008937/doc4.xml","form_type":"4"}},{"id":2401450,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":66503,"kind":"person","name":"King Andrew James","position":1,"cik":"0001823187","reported_name":"King Andrew James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2022-02-11T17:26:33.000Z","date":"2022-02-10","kind":"exercise","acquired":true,"shares":2500,"price":0.35,"value":875.0,"ownership":{"direct":true},"balance_after":6594,"source":{"system":"sec-edgar","filing":"0001209191-22-008937","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000120919122008937/doc4.xml","form_type":"4"}},{"id":2416340,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":66503,"kind":"person","name":"King Andrew James","position":1,"cik":"0001823187","reported_name":"King Andrew James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock (RSU)(Common Stock)","published_at":"2022-02-02T17:22:36.000Z","date":"2022-01-31","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vests as to one-third (1/3) of the total restricted stock units in equal annual installments beginning on January 31, 2023, until fully vested, subject to the reporting person's provision of service to the Issuer on each vesting date."}],"balance_after":25000,"derivative":{"expiration_date":"2025-01-31","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-22-006443","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000120919122006443/doc4.xml","form_type":"4"}},{"id":2416339,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":66503,"kind":"person","name":"King Andrew James","position":1,"cik":"0001823187","reported_name":"King Andrew James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-02-02T17:22:36.000Z","date":"2022-01-31","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 25% of the total shares on January 31, 2023, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":100000,"derivative":{"exercise_price":12.9,"expiration_date":"2032-01-30","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001209191-22-006443","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000120919122006443/doc4.xml","form_type":"4"}},{"id":2514851,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":66503,"kind":"person","name":"King Andrew James","position":1,"cik":"0001823187","reported_name":"King Andrew James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-11-12T19:59:18.000Z","date":"2021-11-09","kind":"exercise","acquired":false,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vested as to 25% of the total shares on May 6, 2020, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date."}],"balance_after":70547,"derivative":{"exercise_price":0.35,"expiration_date":"2029-06-05","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001209191-21-064363","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000120919121064363/doc4.xml","form_type":"4"}},{"id":2514850,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":66503,"kind":"person","name":"King Andrew James","position":1,"cik":"0001823187","reported_name":"King Andrew James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-11-12T19:59:18.000Z","date":"2021-11-09","kind":"sale","acquired":false,"shares":5000,"price":13.5319,"value":67659.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.29 to $13.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein."}],"balance_after":4094,"source":{"system":"sec-edgar","filing":"0001209191-21-064363","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000120919121064363/doc4.xml","form_type":"4"}},{"id":2514849,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":66503,"kind":"person","name":"King Andrew James","position":1,"cik":"0001823187","reported_name":"King Andrew James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-11-12T19:59:18.000Z","date":"2021-11-09","kind":"exercise","acquired":true,"shares":2500,"price":0.35,"value":875.0,"ownership":{"direct":true},"balance_after":9094,"source":{"system":"sec-edgar","filing":"0001209191-21-064363","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000120919121064363/doc4.xml","form_type":"4"}},{"id":2545428,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":66503,"kind":"person","name":"King Andrew James","position":1,"cik":"0001823187","reported_name":"King Andrew James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units (RSU)","published_at":"2021-10-08T18:48:14.000Z","date":"2021-10-06","kind":"exercise","acquired":false,"shares":10151,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs vests as to one-third (1/3) of the total restricted stock units in equal annual installments beginning on October 6, 2021, until fully vested subject to the reporting person's provision of service to the Issuer on each vesting date."}],"balance_after":20304,"derivative":{"expiration_date":"2030-10-05","underlying":"Common Stock","underlying_shares":10151},"source":{"system":"sec-edgar","filing":"0001209191-21-060112","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000120919121060112/doc4.xml","form_type":"4"}},{"id":2545427,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":66503,"kind":"person","name":"King Andrew James","position":1,"cik":"0001823187","reported_name":"King Andrew James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-10-08T18:48:14.000Z","date":"2021-10-06","kind":"tax_withholding","acquired":false,"shares":3557,"price":12.3686,"value":43995.1102,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a \"sell to cover\" transaction and do not represent discretionary trades by the Reporting Person."}],"balance_after":6594,"source":{"system":"sec-edgar","filing":"0001209191-21-060112","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000120919121060112/doc4.xml","form_type":"4"}},{"id":2545426,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":66503,"kind":"person","name":"King Andrew James","position":1,"cik":"0001823187","reported_name":"King Andrew James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-10-08T18:48:14.000Z","date":"2021-10-06","kind":"exercise","acquired":true,"shares":10151,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."}],"balance_after":10151,"source":{"system":"sec-edgar","filing":"0001209191-21-060112","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000120919121060112/doc4.xml","form_type":"4"}},{"id":2675495,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":66503,"kind":"person","name":"King Andrew James","position":1,"cik":"0001823187","reported_name":"King Andrew James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2021-06-09T18:14:17.000Z","date":"2021-06-07","kind":"grant","acquired":true,"shares":21500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 25% of the total shares on June 7, 2022, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":21500,"derivative":{"exercise_price":17.59,"expiration_date":"2031-06-06","underlying":"Common Stock","underlying_shares":21500},"source":{"system":"sec-edgar","filing":"0001209191-21-039258","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000120919121039258/doc4.xml","form_type":"4"}},{"id":2863108,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":66503,"kind":"person","name":"King Andrew James","position":1,"cik":"0001823187","reported_name":"King Andrew James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Head of Renal Discovery"}}],"security":"Restricted Stock (RSU)(Common Stock)","published_at":"2021-02-12T18:11:47.000Z","date":"2021-02-10","kind":"grant","acquired":true,"shares":20406,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vests as to one-third (1/3) of the total restricted stock units in equal annual installments beginning on February 10, 2022, until fully vested, subject to the reporting person's provision of service to the Issuer on each vesting date."}],"balance_after":20406,"derivative":{"expiration_date":"2024-02-10","underlying":"Common Stock","underlying_shares":20406},"source":{"system":"sec-edgar","filing":"0001209191-21-010387","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000120919121010387/doc4.xml","form_type":"4"}},{"id":2863107,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":66503,"kind":"person","name":"King Andrew James","position":1,"cik":"0001823187","reported_name":"King Andrew James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Head of Renal Discovery"}}],"security":"Stock Option (right to buy)","published_at":"2021-02-12T18:11:47.000Z","date":"2021-02-10","kind":"grant","acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 25% of the total shares on February 10, 2022, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":60000,"derivative":{"exercise_price":15.14,"expiration_date":"2031-02-09","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001209191-21-010387","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000120919121010387/doc4.xml","form_type":"4"}},{"id":3010800,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":66503,"kind":"person","name":"King Andrew James","position":1,"cik":"0001823187","reported_name":"King Andrew James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Head of Renal Discovery"}}],"security":"Restricted Stock Units (RSU)(Common Stock)","published_at":"2020-10-07T21:01:01.000Z","date":"2020-10-06","kind":"grant","acquired":true,"shares":30455,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The RSUs vests as to one-third (1/3) of the total restricted stock units in equal annual installments beginning on October 6, 2021, until fully vested subject to the reporting person's provision of service to the Issuer on each vesting date."}],"balance_after":30455,"derivative":{"expiration_date":"2030-10-05","underlying":"Common Stock","underlying_shares":30455},"source":{"system":"sec-edgar","filing":"0001209191-20-054247","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000120919120054247/doc4.xml","form_type":"4"}},{"id":3010799,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":66503,"kind":"person","name":"King Andrew James","position":1,"cik":"0001823187","reported_name":"King Andrew James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Head of Renal Discovery"}}],"security":"Stock Option (right to buy)","published_at":"2020-10-07T21:01:01.000Z","date":"2020-10-06","kind":"grant","acquired":true,"shares":89545,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The stock option vests as to 25% of the total shares on October 6, 2021, and thereafter vests as to 1/36 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":89545,"derivative":{"exercise_price":14.77,"expiration_date":"2030-10-05","underlying":"Common Stock","underlying_shares":89545},"source":{"system":"sec-edgar","filing":"0001209191-20-054247","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000120919120054247/doc4.xml","form_type":"4"}},{"id":3010798,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":66503,"kind":"person","name":"King Andrew James","position":1,"cik":"0001823187","reported_name":"King Andrew James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Head of Renal Discovery"}}],"security":"Stock Option (right to buy)","published_at":"2020-10-07T21:01:01.000Z","date":"2020-10-05","kind":"grant","acquired":true,"shares":73047,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Received in connection with the Merger in exchange for a stock option to acquire 250,000\nshares of Private Chinook common stock for $0.12 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vests as to 25% of the total shares on March 6, 2021, and thereafter vests as to 1/48 of the total shares monthly until fully\nvested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":73047,"derivative":{"exercise_price":0.42,"expiration_date":"2030-03-18","underlying":"Common Stock","underlying_shares":73047},"source":{"system":"sec-edgar","filing":"0001209191-20-054247","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000120919120054247/doc4.xml","form_type":"4"}},{"id":3010797,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":66503,"kind":"person","name":"King Andrew James","position":1,"cik":"0001823187","reported_name":"King Andrew James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Head of Renal Discovery"}}],"security":"Stock Option (right to buy)","published_at":"2020-10-07T21:01:01.000Z","date":"2020-10-05","kind":"grant","acquired":true,"shares":73047,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Received in connection with the merger of Private Chinook into the Issuer (the \"Merger\") in exchange for a stock option to acquire 250,000\nshares of Private Chinook common stock for $0.10 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vested as to 25% of the total shares on May 6, 2020, and thereafter vests as to 1/48 of the total shares monthly until fully\nvested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":73047,"derivative":{"exercise_price":0.35,"expiration_date":"2029-06-05","underlying":"Common Stock","underlying_shares":73047},"source":{"system":"sec-edgar","filing":"0001209191-20-054247","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000120919120054247/doc4.xml","form_type":"4"}}]}